Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis.

Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martino M, Waldert M, Marberger M, Susani M, Haitel A.

Am J Clin Pathol. 2012 May;137(5):761-8. doi: 10.1309/AJCPQ6LLFMC4OXGC.

PMID:
22523215
2.

TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.

Rao Q, Williamson SR, Zhang S, Eble JN, Grignon DJ, Wang M, Zhou XJ, Huang W, Tan PH, Maclennan GT, Cheng L.

Am J Surg Pathol. 2013 Jun;37(6):804-15. doi: 10.1097/PAS.0b013e31827e17cb.

PMID:
23598965
3.

Usefulness of a break-apart FISH assay in the diagnosis of Xp11.2 translocation renal cell carcinoma.

Kim SH, Choi Y, Jeong HY, Lee K, Chae JY, Moon KC.

Virchows Arch. 2011 Sep;459(3):299-306. doi: 10.1007/s00428-011-1127-5. Epub 2011 Jul 20.

PMID:
21773754
4.

Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum.

Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, Eble JN, Bonsib SM, Jimeno M, Lloreta J, Billis A, Hicks J, De Marzo AM, Reuter VE, Ladanyi M.

Am J Surg Pathol. 2007 Aug;31(8):1149-60.

PMID:
17667536
5.

Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome.

Mir MC, Trilla E, de Torres IM, Panizo A, Zlotta AR, Van Rhijn B, Morote J.

BJU Int. 2011 Jul;108(2 Pt 2):E71-6. doi: 10.1111/j.1464-410X.2010.09818.x. Epub 2010 Nov 10.

6.

Molecular heterogeneity of TFE3 activation in renal cell carcinomas.

Macher-Goeppinger S, Roth W, Wagener N, Hohenfellner M, Penzel R, Haferkamp A, Schirmacher P, Aulmann S.

Mod Pathol. 2012 Feb;25(2):308-15. doi: 10.1038/modpathol.2011.169. Epub 2011 Oct 28.

7.

Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry.

Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, Yamamoto S, Migita T, Ishikawa Y, Kurata M, Nakamura T, Fukui I.

Clin Cancer Res. 2009 Feb 15;15(4):1170-6. doi: 10.1158/1078-0432.CCR-08-1183.

8.

Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.

Green WM, Yonescu R, Morsberger L, Morris K, Netto GJ, Epstein JI, Illei PB, Allaf M, Ladanyi M, Griffin CA, Argani P.

Am J Surg Pathol. 2013 Aug;37(8):1150-63. doi: 10.1097/PAS.0b013e31828a69ae.

PMID:
23715164
9.

Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.

Altinok G, Kattar MM, Mohamed A, Poulik J, Grignon D, Rabah R.

Pediatr Dev Pathol. 2005 Mar-Apr;8(2):168-80. Epub 2005 Mar 8.

PMID:
15747097
10.

XP11.2 translocation renal cell carcinoma: clinical experience of Taipei Veterans General Hospital.

Hung CC, Pan CC, Lin CC, Lin AT, Chen KK, Chang YH.

J Chin Med Assoc. 2011 Nov;74(11):500-4. doi: 10.1016/j.jcma.2011.09.005. Epub 2011 Nov 1.

11.

Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels.

Kuroda N, Tamura M, Tanaka Y, Hes O, Michal M, Inoue K, Ohara M, Mizuno K, Lee GH.

Pathol Int. 2009 Jul;59(7):486-91. doi: 10.1111/j.1440-1827.2009.02398.x.

PMID:
19563413
12.

Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.

Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D, Pea M, Bonetti F, Illei PB, Netto GJ, Ladanyi M, Chilosi M, Argani P.

Mod Pathol. 2011 Oct;24(10):1313-9. doi: 10.1038/modpathol.2011.93. Epub 2011 May 20.

13.

Pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.

Winarti NW, Argani P, De Marzo AM, Hicks J, Mulyadi K.

Int J Surg Pathol. 2008 Jan;16(1):66-72. doi: 10.1177/1066896907304994.

PMID:
18203790
14.

Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.

Hodge JC, Pearce KE, Wang X, Wiktor AE, Oliveira AM, Greipp PT.

Mod Pathol. 2014 Jan;27(1):113-27. doi: 10.1038/modpathol.2013.83. Epub 2013 Jul 5.

15.

Validation of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinomas.

Mosquera JM, Dal Cin P, Mertz KD, Perner S, Davis IJ, Fisher DE, Rubin MA, Hirsch MS.

Diagn Mol Pathol. 2011 Sep;20(3):129-37. doi: 10.1097/PDM.0b013e31820e9c67.

PMID:
21817901
16.

[Research advances in Xp11.2 translocation renal cell carcinoma].

Huang JH, Zhou FJ.

Ai Zheng. 2008 Sep;27(9):1006-8. Review. Chinese.

PMID:
18799045
17.

A case of bilateral renal cell carcinoma associated with long-term dialysis showing false-positive immunoreactivity for TFE3 as Xp11 translocation renal cell carcinoma.

Kurisaki-Arakawa A, Saito T, Takahashi M, Mitani K, Fukumura Y, Nagashima Y, Argani P, Yao T.

Int J Clin Exp Pathol. 2013 Oct 15;6(11):2585-90. eCollection 2013.

18.

Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.

Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, Pan CC, Netto G, Doglioni C, Hes O, Argani P, Chilosi M.

Mod Pathol. 2009 Aug;22(8):1016-22. doi: 10.1038/modpathol.2009.58. Epub 2009 Apr 24.

19.

A novel case of t(X;1)(p11.2;p34) in a renal cell carcinoma with TFE3 rearrangement and favorable outcome in a 57-year-old patient.

Haudebourg J, Hoch B, Fabas T, Burel-Vandenbos F, Carpentier X, Amiel J, Cardot-Leccia N, Michiels JF, Pedeutour F.

Cancer Genet Cytogenet. 2010 Jul 15;200(2):75-8. doi: 10.1016/j.cancergencyto.2010.03.011.

PMID:
20620589
20.

[Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].

Rao Q, Zhou J, Zhang RS, Ma HH, Zhou HB, Lu ZF, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2010 Sep;39(9):582-6. Chinese.

PMID:
21092583

Supplemental Content

Support Center